Rosuvastatin ORBITAL Germany

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Hypercholesterolemia

Treatments: Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00379249

ORBITAL

D3560L00001

Details and patient eligibility

About

The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• high cholesterol with an indication for cholesterol-lowering medication (statins)

Exclusion criteria

• contra-indications for statin therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)